Startup Behind Oxford-AstraZeneca Covid-19 Vaccine Files for U.S. IPO

 The biotech startup behind the Covid-19 vaccine jointly developed by AstraZeneca PLC and the University of Oxford filed Friday with U.S. regulators for a public share offering.

Vaccitech PLC said in a securities filing it plans to use the technology underpinning the vaccine to develop treatments targeting prostate cancer, hepatitis B and human papillomavirus. The Wall Street Journal reported Wednesday that the IPO filing could come as soon as this week. The U.K.-based company plans to list on New York's Nasdaq with the ticker symbol VACC.

https://www.marketscreener.com/quote/stock/ASTRAZENECA-PLC-4000930/news/Startup-Behind-Oxford-AstraZeneca-Covid-19-Vaccine-Files-for-U-S-IPO-32928864/